---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002835"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:32:45.623353+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aclaris Phase 2a zunsemetinib trial for hidradenitis suppurativa fails to meet endpoints

## Summary
- Study did not meet primary endpoint of change in inflammatory nodule/abscess count at week 12.
- Secondary endpoints including HiSCR-50 also not met; placebo effect higher than in published HS studies.
- Zunsemetinib generally well tolerated; most common AEs: dizziness (16.7%), diarrhea (12.5%), headache (12.5%).
- No serious adverse events or opportunistic infections observed; PK/PD consistent with prior studies.
- CEO notes next data readout from Phase 2b rheumatoid arthritis study is expected.

## SEC filing metadata
- accession: 0001558370-23-002835
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023002835/0001558370-23-002835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023002835/acrs-20230306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002835
- JSON: https://secwatch.observer/filing/0001558370-23-002835.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.